top
Search terms
Results 1 - 10 of 11 - ordered by :
Pages: 1 2
Ehjournal

Aims The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and treatment effects. Notable differences included: WE patients (mean age 68 ...

European Heart Journal, Kristensen, Søren Lund, Martinez, Felipe, Jhund, Pardeep S., Arango, Juan Luis, Bĕlohlávek, Jan, Boytsov, Sergey, Cabrera, Walter, Gomez, Efrain, Hagège, Albert ...

Date : 01/11/2016 Item size : 314421 bytes
Ehjournal

Aims The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and treatment effects. Notable differences included: WE patients (mean age 68 ...

European Heart Journal, Kristensen, Søren Lund, Martinez, Felipe, Jhund, Pardeep S., Arango, Juan Luis, Bĕlohlávek, Jan, Boytsov, Sergey, Cabrera, Walter, Gomez, Efrain, Hagège, Albert ...

Date : 01/11/2016 Item size : 343831 bytes
Ejhf

Aims The combined neprilysin/renin–angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all-cause ...

European Journal of Heart Failure, Solomon, Scott D., Claggett, Brian, McMurray, John J.V., Hernandez, Adrian F., Fonarow, Gregg C.

Date : 01/10/2016 Item size : 46771 bytes
Ejhf

Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial Introduction The prognostic ...

European Journal of Heart Failure, Cannon, Jane A., Shen, Li, Jhund, Pardeep S., Anand, Inder S., Komajda, Michel, McKelvie, Robert S., Zile, Michael R., Carson, Peter E., McMurray, John J.V.

Date : 01/08/2016 Item size : 196742 bytes
Ejhf

Aim We aimed to study the relationships of loop diuretic dose with renal function and clinical outcomes in patients with chronic heart failure (HF). The relationship to change in estimated ...

European Journal of Heart Failure, Damman, Kevin, Kjekshus, John, Wikstrand, John, Cleland, John G.F., Komajda, Michel, Wedel, Hans, Waagstein, Finn, McMurray, John J.V.

Date : 01/03/2016 Item size : 50791 bytes
Ehjournal

[...]ivabradine should lead to little or no improvement in outcomes in any other population defined by the presence of CAD but by the absence of LVSD (so as to allow dissection of any effect of ...

European Heart Journal, McMurray, John J.V.

Date : 14/08/2015 Item size : 130148 bytes
Ehjournal

[...]ivabradine should lead to little or no improvement in outcomes in any other population defined by the presence of CAD but by the absence of LVSD (so as to allow dissection of any effect of ...

European Heart Journal, McMurray, John J.V.

Date : 14/08/2015 Item size : 165732 bytes
Ejhf

Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS‐HF) Original ArticleAuthors Jane A. ...

European Journal of Heart Failure, Cannon, Jane A., Collier, Timothy J., Shen, Li, Swedberg, Karl, Krum, Henry, Van Veldhuisen, Dirk J., Vincent, John, Pocock, Stuart J., Pitt, Bertram, Zannad, ...

Date : 01/07/2015 Item size : 180262 bytes
Ejhf

Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS‐HF) Original ArticleAuthors Jane A. ...

European Journal of Heart Failure, Cannon, Jane A., Collier, Timothy J., Shen, Li, Swedberg, Karl, Krum, Henry, Van Veldhuisen, Dirk J., Vincent, John, Pocock, Stuart J., Pitt, Bertram, Zannad, ...

Date : 01/07/2015 Item size : 185136 bytes
Ejhf

The use of disease-specific composite mortality–morbidity endpoints instead of all-cause mortality was largely pioneered in these trials.2–7 Similarly, in order to achieve sufficient power in an ...

European Journal of Heart Failure, McMurray, John J.V., Swedberg, Karl

Date : 01/02/2010 Item size : 106488 bytes